🚀 VC round data is live in beta, check it out!
NextCell Pharma Valuation Multiples
Discover revenue and EBITDA valuation multiples for NextCell Pharma and similar public comparables like Jupiter Neurosciences, Abera Bioscience, Biogened, NFL Biosciences and more.
NextCell Pharma Overview
About NextCell Pharma
NextCell Pharma AB is a healthcare services provider. The company is engaged in the research of stem cell and is developing the candidate drug ProTrans for the treatment of diabetes and immunosuppression in kidney transplants.
Founded
2014
HQ
Employees
8
Website
Sectors
Financials (LTM)
EV
$13M
NextCell Pharma Financials
NextCell Pharma reported last 12-month revenue of $2M and negative EBITDA of ($3M).
In the same LTM period, NextCell Pharma generated $606K in gross profit, ($3M) in EBITDA losses, and had net loss of ($4M).
Revenue (LTM)
NextCell Pharma P&L
In the most recent fiscal year, NextCell Pharma reported revenue of $1M and EBITDA of ($3M).
NextCell Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $2M | XXX | $1M | XXX | XXX | XXX |
| Gross Profit | $606K | XXX | $168K | XXX | XXX | XXX |
| Gross Margin | 38% | XXX | 14% | XXX | XXX | XXX |
| EBITDA | ($3M) | XXX | ($3M) | XXX | XXX | XXX |
| EBITDA Margin | (217%) | XXX | (283%) | XXX | XXX | XXX |
| EBIT Margin | (301%) | XXX | (304%) | XXX | XXX | XXX |
| Net Profit | ($4M) | XXX | ($4M) | XXX | XXX | XXX |
| Net Margin | (234%) | XXX | (304%) | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
NextCell Pharma Stock Performance
NextCell Pharma has current market cap of $16M, and enterprise value of $13M.
Market Cap Evolution
NextCell Pharma's stock price is $0.14.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $13M | $16M | -4.1% | XXX | XXX | XXX | $-0.03 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialNextCell Pharma Valuation Multiples
NextCell Pharma trades at 8.1x EV/Revenue multiple, and (3.8x) EV/EBITDA.
EV / Revenue (LTM)
NextCell Pharma Financial Valuation Multiples
As of April 18, 2026, NextCell Pharma has market cap of $16M and EV of $13M.
Equity research analysts estimate NextCell Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
NextCell Pharma has a P/E ratio of (4.2x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $16M | XXX | $16M | XXX | XXX | XXX |
| EV (current) | $13M | XXX | $13M | XXX | XXX | XXX |
| EV/Revenue | 8.1x | XXX | 10.6x | XXX | XXX | XXX |
| EV/EBITDA | (3.8x) | XXX | (3.8x) | XXX | XXX | XXX |
| EV/EBIT | (2.7x) | XXX | (3.5x) | XXX | XXX | XXX |
| EV/Gross Profit | 21.5x | XXX | 77.8x | XXX | XXX | XXX |
| P/E | (4.2x) | XXX | (4.2x) | XXX | XXX | XXX |
| EV/FCF | — | XXX | (3.1x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified NextCell Pharma Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
NextCell Pharma Margins & Growth Rates
NextCell Pharma's revenue in the last 12 month grew by 1200%.
NextCell Pharma's revenue per employee in the last FY averaged $0.2M, while opex per employee averaged $0.5M for the same period.
NextCell Pharma Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 1200% | XXX | 48% | XXX | XXX | XXX |
| EBITDA Margin | (217%) | XXX | (283%) | XXX | XXX | XXX |
| EBITDA Growth | — | XXX | (15%) | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.2M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.5M | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 331% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
NextCell Pharma Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| NextCell Pharma | XXX | XXX | XXX | XXX | XXX | XXX |
| Jupiter Neurosciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Abera Bioscience | XXX | XXX | XXX | XXX | XXX | XXX |
| Biogened | XXX | XXX | XXX | XXX | XXX | XXX |
| NFL Biosciences | XXX | XXX | XXX | XXX | XXX | XXX |
| Genenta Science | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
NextCell Pharma M&A Activity
NextCell Pharma acquired XXX companies to date.
Last acquisition by NextCell Pharma was on XXXXXXXX, XXXXX. NextCell Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by NextCell Pharma
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialNextCell Pharma Investment Activity
NextCell Pharma invested in XXX companies to date.
NextCell Pharma made its latest investment on XXXXXXXX, XXXXX. NextCell Pharma invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by NextCell Pharma
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout NextCell Pharma
| When was NextCell Pharma founded? | NextCell Pharma was founded in 2014. |
| Where is NextCell Pharma headquartered? | NextCell Pharma is headquartered in Sweden. |
| How many employees does NextCell Pharma have? | As of today, NextCell Pharma has over 8 employees. |
| Is NextCell Pharma publicly listed? | Yes, NextCell Pharma is a public company listed on Nasdaq Stockholm. |
| What is the stock symbol of NextCell Pharma? | NextCell Pharma trades under NXTCL ticker. |
| When did NextCell Pharma go public? | NextCell Pharma went public in 2017. |
| Who are competitors of NextCell Pharma? | NextCell Pharma main competitors are Jupiter Neurosciences, Abera Bioscience, Biogened, NFL Biosciences. |
| What is the current market cap of NextCell Pharma? | NextCell Pharma's current market cap is $16M. |
| What is the current revenue of NextCell Pharma? | NextCell Pharma's last 12 months revenue is $2M. |
| What is the current revenue growth of NextCell Pharma? | NextCell Pharma revenue growth (NTM/LTM) is 1200%. |
| What is the current EV/Revenue multiple of NextCell Pharma? | Current revenue multiple of NextCell Pharma is 8.1x. |
| Is NextCell Pharma profitable? | No, NextCell Pharma is not profitable. |
| What is the current EBITDA of NextCell Pharma? | NextCell Pharma has negative EBITDA and is not profitable. |
| What is NextCell Pharma's EBITDA margin? | NextCell Pharma's last 12 months EBITDA margin is (217%). |
| What is the current EV/EBITDA multiple of NextCell Pharma? | Current EBITDA multiple of NextCell Pharma is (3.8x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.